A New Beginning for Triglyceride-Lowering Therapies

Aruna D. Pradhan, MD, MPH


Circulation. 2019;140(3):167-169. 

In This Article

Abstract and Introduction


The cardiovascular community has been debating for decades whether to treat mild-to-moderate hypertriglyceridemia. Results of the REDUCE-IT study (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial)[1] position this controversy as front matter for deliberation. For lipid experts, dominating the discourse will be the strength of experimental evidence, mechanism of benefit, identification of treatment response parameters, and prioritizing treatment options. For the practitioner, the question ultimately will be whether potential gains are worth the disruption to clinical care that accompanies a new paradigm in prevention.